Subscribe
Home
Issues
Latest Issue
Issue Archive
Special Issues
2022 Midyear Review: Non–Small-Cell Lung Cancer
2022 Oncology Biosimilar Guide to Patient Support Services
2022 Breast Cancer Guide to Patient Support Services
Browse By Topic
Practice Management
Financial Management
Reimbursement
Health Policy
Quality Care
ICD Codes
Survivorship
FDA Approvals, News & Updates
In the News
Guide to Patient Support Services
Index
Introduction
2023 Spotlight
Conference Correspondent
ASCO 2022 - Wrap Up
NSCLC IO 2022 - Midyear Review
SABCS 2021 Wrap-Up
Dual IO 2021 Year in Review
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Rapid Reactions
In the News
Quick Quiz
Multiple Myeloma Monthly Minutes
Melanoma Monthly Minutes
Press Releases
Women's Health Monthly Minutes
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes
Lung Cancer Monthly Minutes
Lung Cancer
Imjudo FDA Approved with Imfinzi and Chemotherapy for Metastatic NSCLC
FDA Approvals, News & Updates
,
Lung Cancer
On
November 10, 2022
, the FDA approved this new immunotherapy, in combination with the PD-L1 inhibitor durvalumab (Imfinzi; AstraZeneca) and platinum-based chemotherapy, for the treatment of adults with metastatic non–small-cell lung cancer (NSCLC) and no
EGFR
or
ALK
genomic alterations.
Read More ›
Libtayo plus Platinum-Based Chemotherapy Now FDA Approved for NSCLC without Genomic Aberrations
FDA Approvals, News & Updates
,
Lung Cancer
On
November 8, 2022
, the FDA approved a new indication for cemiplimab-rwlc (Libtayo; Regeneron), a PD-1 inhibitor, in combination with platinum-based chemotherapy, for the treatment of adults with advanced NSCLC and no
EGFR
,
ALK
, or
ROS1
aberrations.
Read More ›
Neoadjuvant Chemoimmunotherapy May Become New Standard of Care for Patients with Resectable NSCLC
By
Patricia Stewart
Lung Cancer
The phase 3 CheckMate-816 trial establishes a new standard of care for resectable non–small-cell lung cancer (NSCLC): neoadjuvant nivolumab (Opdivo) plus chemotherapy.
Read More ›
2022 Midyear Review: Non–Small-Cell Lung Cancer
Lung Cancer
Read More ›
NSCLC Year in Review Introduction
Lung Cancer
The COVID-19 pandemic continues to impact healthcare across the globe. We are yet to see the full effect of the COVID-19 pandemic on patients with cancer, including patients with non–small-cell lung cancer (NSCLC). With the recent emergence of the COVID-19 Omicron variant, we expect this impact on healthcare and cancer care to continue. The
Year in Review
series is an important tool to reach audiences and provide timely and relevant information on treatment advances in the oncology setting.
Read More ›
The Impact of Symptom Severity on Multidisciplinary Tumor Board Treatment Decisions
Lung Cancer
Multidisciplinary tumor board members work closely to make the best clinical decisions for their patients with cancer to improve patient and institutional outcomes. Their decisions should be based on the clinical data of each patient in line with their own clinical and institutional guidelines.
Read More ›
Targeted Therapy and Immunotherapy May Improve NSCLC Survival Rates
Lung Cancer
Immunotherapy and targeted therapy have resulted in improved survival rates in patients with NSCLC over the past decade.
Read More ›
CodeBreaK 100 Phase 2 Study Results Demonstrate Sotorasib Efficacy
Lung Cancer
Sotorasib showed encouraging anticancer activity in phase 2 of a clinical trial of patients with heavily treated advanced NSCLC.
Read More ›
FDA Grants Accelerated Approval of Sotorasib for Patients with NSCLC Harboring KRAS Mutations
Lung Cancer
Data from the CodeBreaK 100 NSCLC subset population prompted the FDA to grant sotorasib accelerated approval for patients with
KRAS
G12C
mutation–positive NSCLC.
Read More ›
Role of Exercise and Energy Conservation in the Management of Fatigue in Patients with NSCLC Receiving Immune-Oncology Therapy
Lung Cancer
Finding the right balance between cancer-induced fatigue and immune-oncology–induced fatigue and doing enough exercise to improve general health and better cancer outcomes is a fundamental part of treating patients with cancer. Finding this balance for patients with NSCLC receiving immune-oncology therapy is a key element of overall care for these patients.
Read More ›
Page 1 of 12
1
2
3
4
5
6
7
8
9
10
View the Latest Issue of OPM
Read Issue
Top Trending Articles
1.
Specialty Carve-Outs: What Are the Implications for Patients and Practices?
By
Dawn Holcombe, MBA, FACMPE, ACHE
2.
New Policies Regarding Intravenous Iron Replacement Are Creating Conundrum for Providers and Payers
By
Dawn Holcombe, MBA, FACMPE, ACHE
3.
2023 Spotlight: Amgen
Home
Issues
Latest Issue
Issue Archive
Special Issues
2022 Midyear Review: Non–Small-Cell Lung Cancer
2022 Oncology Biosimilar Guide to Patient Support Services
2022 Breast Cancer Guide to Patient Support Services
Browse By Topic
Practice Management
Financial Management
Reimbursement
Health Policy
Quality Care
ICD Codes
Survivorship
FDA Approvals, News & Updates
In the News
Guide to Patient Support Services
Index
Introduction
2023 Spotlight
Conference Correspondent
ASCO 2022 - Wrap Up
NSCLC IO 2022 - Midyear Review
SABCS 2021 Wrap-Up
Dual IO 2021 Year in Review
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Rapid Reactions
In the News
Quick Quiz
Multiple Myeloma Monthly Minutes
Melanoma Monthly Minutes
Press Releases
Women's Health Monthly Minutes
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes